Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 59.47 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 95.08 | Oscillator | Sell |
| Williams %R (14) | -4.83 | Oscillator | Sell |
| MACD (12, 26, 9) | -0.67 (Hist 2.95) | Oscillator | Buy |
| Average Directional Index (14) | 28.24 (+DI 26.6 / -DI 17.9) | Trend | Strong Buy |
| EMA 20 | 233.73 | MA | Strong Buy |
| SMA 20 | 229.71 | MA | Strong Buy |
| EMA 50 | 238.74 | MA | Buy |
| SMA 50 | 242.60 | MA | Buy |
| SMA 200 | 237.14 | MA | Buy |
Current price $243.37
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 25, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Sep 15, 26 | Raymond James | downgrade | Strong Buy | Outperform |
| Sep 2, 26 | Oppenheimer | maintain | Outperform | Outperform |
| Sep 1, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Sep 1, 26 | Wedbush | maintain | Outperform | Outperform |
| Aug 31, 26 | Jefferies | maintain | Buy | Buy |
| Aug 31, 26 | Stifel | maintain | Buy | Buy |
| Aug 31, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 31, 26 | B of A Securities | maintain | Buy | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | ASND | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 18.0x | -22.3x · sector 20.7x | In line |
| Forward P/E (FY26E) | 16.6x | EPS est. 14.62 | In line |
| Price / Book | 9.7x | -30.6x | Discount |
| Price / Sales | 12.8x | 203.8x | Discount |
| EV / EBITDA | 168.8x | -35.2x | Discount |
| Return on equity | 190.4% | — | Top tier |
| Gross margin | 90.2% | 77.5% | Above hist. |
| Debt / Equity | 0.31 | -3.20 | Conservative |
| Piotroski / Altman Z | 6/9 | Z 9.44 | Safe zone |
Discounted cash flow model
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Oct 16, 2026 | 2026-10-16 14:58:52 | View |
| 6-K | Oct 14, 2026 | 2026-10-14 17:02:36 | View |
| 6-K | Sep 29, 2026 | 2026-09-29 16:02:27 | View |
| 4 | Sep 28, 2026 | 2026-09-28 16:08:12 | View |
| 6-K | Sep 15, 2026 | 2026-09-14 18:31:18 | View |
| 6-K | Sep 15, 2026 | 2026-09-14 18:30:02 | View |
| 6-K | Sep 9, 2026 | 2026-09-09 17:21:18 | View |
| 4 | Sep 9, 2026 | 2026-09-09 17:04:07 | View |
| 6-K | Sep 9, 2026 | 2026-09-09 16:03:39 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:09:06 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma's Marketing Authorisation Application (MAA) is expected during Q4 2026.
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | 1.71 | 3.29 | Beat 92.4% | $387.5M |
| May 7, 2026 | 0.19 | 0.32 | Beat 70.6% | $284.9M |
| Feb 11, 2026 | -0.06 | -0.64 | Miss -966.7% | $344.8M |
| Nov 12, 2025 | -0.41 | -1.17 | Miss -185.4% | $250.2M |
| Aug 7, 2025 | -1.42 | -0.93 | Beat 34.5% | $186.1M |
| May 1, 2025 | -1.56 | -1.66 | Miss -6.4% | $110.7M |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Apr 14, 26 | Bienaime Jean Jacques | director | A-Award | 9,160 @ $249.84 | $2.29M |
| Apr 14, 26 | Bienaime Jean Jacques | director | D-Return | 9,160 @ $172.35 | $1.58M |
| Sep 8, 26 | Bodenhoff Mads | officer: SVP & PAO | M-Exempt | 3,000 @ $110.00 | $330.0K |
| Sep 8, 26 | Bodenhoff Mads | officer: SVP & PAO | M-Exempt | 3,000 @ $110.00 | $330.0K |
| Sep 8, 26 | Bodenhoff Mads | officer: SVP & PAO | S-Sale | 3,000 @ $270.19 | $810.6K |
| Sep 2, 26 | Holtug Lars | director | S-Sale | 236 @ $264.13 | $62.33K |
| Aug 14, 26 | Bienaime Jean Jacques | director | P-Purchase | 900 @ $246.91 | $222.2K |
| Aug 14, 26 | Bienaime Jean Jacques | director | P-Purchase | 1,100 @ $245.85 | $270.4K |